Guang Peng, M.D., Ph.D.
Department of Experimental Therapeutics, Division of Cancer Medicine
About Dr. Guang Peng
Guang Peng is a professor in the Department of Clinical Cancer Prevention at The University of Texas MD Anderson Cancer Center. She completed her Bachelor’s degree in medicine from Tongji Medical University, Wuhan, China. She received her PhD degree in biomedical sciences from University of South Carolina, Columbia, SC, USA. The long-term goal of her research is to characterize and target molecular regulators of the mutational and dysfunctional DNA repair processes driving tumor evolution and immune responses.
Present Title & Affiliation
Primary Appointment
Professor, Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Regular Member, The University of Texas Graduate School of Biomedical Sciences (GSBS), Houston, TX
Research Interests
The overall goal of my laboratory is to understand the causes and consequences of genomic instability and the impact of genomic instability on evolvability and immune phenotypes of cancer cells in the evolutionary process of tumorigenesis. More specifically, by understanding and targeting the DNA repair network, our research aims to address two key questions: (1) Can we identify genetic alterations in the genome maintenance mechanisms that drive tumor evolution, particularly during the transition from premalignant lesions to cancer? (2) Can we identify targeted prevention/therapeutic strategies by modulating evolvability and immune phenotypes? Recent work in my laboratory explores the following directions:
1. Identify genetic alterations in the genome maintenance mechanisms that confers tumor evolvability and alters tumor immune phenotypes: We aim to investigate the novel functions of chromatin remodeling complex SWI/SNF, human nucleases/helicases DNA2 and mutational enzyme APOBEC3B in promoting tumorigenesis by both in vitro and in vivo studies, which may lead to identification of new strategy for early detection and intervention. We are also work to understand how environmental and endogenous factors reshape the landscape of cellular genome by targeting epigenetic regulatory machineries.
2. Discover novel agents targeting the genome maintenance mechanisms by genetic and chemical approaches: We aim to utilize chemical screening and bioinformatics’ tools as our drug-discovery platforms to systematically identify chemical compounds that target the DNA damage response and repair network. We will determine whether the reduction of cellular tolerance to endogenous DNA damage and altered immune responsiveness by modulating DNA repair process would open new avenues for cancer prevention and therapy.
3. Develop systems biology approaches to understand the dynamics of the genome maintenance mechanisms in tumor evolvability and immunoresponsiveness: We aim to utilize mathematical modeling, systems biology and molecular biology approaches to understand and target the DNA damage response and repair network. These new interdisciplinary approaches will offer a revolutionary conceptual framework to determine the compound effect of the DNA repair network rather than focusing on an individual repair gene’s function in tumor evolution and anti-tumor immunity.
Education & Training
Degree-Granting Education
| 2005 | University of South Carolina School of Medicine, Columbia, SC, USA, PHD, Biomedical Sciences |
| 2002 | Tongji Medical University, Wuhan, CHN, MD, Bachelor of Medicine (M.D. Equivalent) |
Postgraduate Training
| 2006-2011 | Postdoc, Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2005-2006 | Postdoc, Cancer Biology, Fox Chase Cancer Center, Philadelphia, PA |
Experience & Service
Academic Appointments
Associate Professor, Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2023
Assistant Professor, Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2017
Honors & Awards
| 2020 | David H. Koch Center for Applied Research of Genitourinary Cancers Research Award |
| 2019 | Distinguished Doctorate Alumni Award, School of Medicine, University of South Carolina |
| 2019 | Kidney Cancer Association Advanced Discovery Award |
| 2018 | Endometrial Cancer SPORE Research Development Award, NIH/NCI |
| 2015 | Investigator-Initiated Research Award, Department of Defense (DoD) Ovarian Cancer Research Program |
| 2015 | Leading Mentor in Cancer Prevention, Honorable Mention |
| 2014 | Susan G. Komen Career Catalyst Research Award |
| 2013 | Ovarian Cancer SPORE Career Development Award, NIH/NCI |
| 2012 | Landon Foundation-AACR Innovator Award for Cancer Prevention Research |
| 2012 | Texas Business Women Award, Texas Business Women Inc |
| 2011 | Howard Temin Pathway to Independence Award, National Cancer Institute |
| 2010 | Trainee of the Quarter, University of Texas MD Anderson Cancer Center |
| 2009 | Trainee Excellence Award, University of Texas MD Anderson Cancer Center |
| 2008 | Oral Presentation Award, Society of Chinese Bioscientists in America Annual Symposia, Houston, TX |
| 2008 | Postdoctoral Fellowship, Susan G. Komen for the Cure Foundation |
| 2006 | First Place in Oral Presentation, Fox Chase Cancer Center Postdoctoral and Graduate Student Research Conference, Philadelphia, PA |
| 2006 | Edward David Lustbader Prize, Fox Chase Cancer Center, Philadelphia, PA |
| 2005 | W. Morgan Newton Research Award, School of Medicine, University of South Carolina |
| 2005 | First Place in Oral Presentation, Graduate Student Day, The Graduate School, University of South Carolina |
| 2004 | Best Student Poster Presentation, Annual South Carolina Alliance for Cancer Chemoprevention Symposium |
Selected Publications
Peer-Reviewed Articles
- Zhao M, Medeiros LJ, Wang W, Tang G, Jung HS, Sfamenos SM, Fang H, Toruner GA, Hu S, Yin CC, Lin P, Gu J, Peng G, You MJ, Khoury JD, Wang SA, Tang Z. Newly designed breakapart FISH probe helps to identify cases with true MECOM rearrangement in myeloid malignancies. Cancer Genet 262-263:23-29, 2022. e-Pub 2021. PMID: 34974290.
- Dong X, Song S, Li Y, Fan Y, Wang L, Wang R, Huo L, Scott A, Xu Y, Pizzi MP, Ma L, Wang Y, Jin J, Zhao W, Yao X, Johnson RL, Wang L, Wang Z, Peng G, Ajani JA. Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting ARID1A deficiency. Gut 71(3):467-478, 2022. e-Pub 2021. PMID: 33785559.
- Ngoi NYL, Peng G, Yap TA. A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade. Annu Rev Med 73:231-250, 2022. e-Pub 2021. PMID: 34644155.
- Mo Q, Wan L, Schell MJ, Jim H, Tworoger SS, Peng G. Integrative Analysis Identifies Multi-Omics Signatures That Drive Molecular Classification of Uveal Melanoma. Cancers (Basel) 13(24), 2021. e-Pub 2021. PMID: 34944787.
- Hao D, He S, Harada K, Pizzi MP, Lu Y, Guan P, Chen L, Wang R, Zhang S, Sewastjanow-Silva M, Abdelhakeem A, Shanbhag N, Bhutani M, Han G, Lee JH, Zhao S, Weston B, Blum Murphy M, Waters R, Estrella JS, Roy-Chowdhuri S, Gan Q, Lee JS, Peng G, Hanash SM, Calin GA, Song X, Zhang J, Song S, Wang L, Ajani JA. Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma. Gut 70(11):2055-2065, 2021. e-Pub 2020. PMID: 33334899.
- Pham MM, Ngoi NYL, Peng G, Tan DSP, Yap TA. Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises. Trends Cancer 7(10):958-970, 2021. e-Pub 2021. PMID: 34158277.
- Yang RK, Toruner GA, Wang W, Fang H, Issa GC, Wang L, Quesada AE, Thakral B, Patel KP, Peng G, Liu S, Yin CC, Borthakur G, Tang Z, Wang SA, Miranda RN, Khoury JD, Medeiros LJ, Tang G. CBFB Break-Apart FISH Testing: An Analysis of 1629 AML Cases with a Focus on Atypical Findings and Their Implications in Clinical Diagnosis and Management. Cancers (Basel) 13(21), 2021. e-Pub 2021. PMID: 34771519.
- Han G, Yang G, Hao D, Lu Y, Thein K, Simpson BS, Chen J, Sun R, Alhalabi O, Wang R, Dang M, Dai E, Zhang S, Nie F, Zhao S, Guo C, Hamza A, Czerniak B, Cheng C, Siefker-Radtke A, Bhat K, Futreal A, Peng G, Wargo J, Peng W, Kadara H, Ajani J, Swanton C, Litchfield K, Ahnert JR, Gao J, Wang L. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun 12(1):5606, 2021. e-Pub 2021. PMID: 34556668.
- Yang B, Li X, Fu Y, Guo E, Ye Y, Li F, Liu S, Xiao R, Liu C, Lu F, Huang J, Qin T, Han L, Peng G, Mills GB, Sun C, Chen G. MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors. Cancer Res 81(10):2714-2729, 2021. e-Pub 2021. PMID: 33589518.
- Wang R, Dang M, Harada K, Han G, Wang F, Pool Pizzi M, Zhao M, Tatlonghari G, Zhang S, Hao D, Lu Y, Zhao S, Badgwell BD, Blum Murphy M, Shanbhag N, Estrella JS, Roy-Chowdhuri S, Abdelhakeem AAF, Wang Y, Peng G, Hanash S, Calin GA, Song X, Chu Y, Zhang J, Li M, Chen K, Lazar AJ, Futreal A, Song S, Ajani JA, Wang L. Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nat Med 27(1):141-151, 2021. e-Pub 2021. PMID: 33398161.
- Ajani JA, Xu Y, Huo L, Wang R, Li Y, Wang Y, Pizzi MP, Scott A, Harada K, Ma L, Yao X, Jin J, Zhao W, Dong X, Badgwell BD, Shanbhag N, Tatlonghari G, Estrella JS, Roy-Chowdhuri S, Kobayashi M, Vykoukal JV, Hanash SM, Calin GA, Peng G, Lee JS, Johnson RL, Wang Z, Wang L, Song S. YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition. Gut 70(1):55-66, 2021. e-Pub 2020. PMID: 32345613.
- Mo Q, Li R, Adeegbe DO, Peng G, Chan KS. Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy. Commun Biol 3(1):784, 2020. e-Pub 2020. PMID: 33335285.
- Wang L, Yang L, Wang C, Zhao W, Ju Z, Zhang W, Shen J, Peng Y, An C, Luu YT, Song S, Yap TA, Ajani JA, Mills GB, Shen X, Peng G. Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors. J Clin Invest 130(11):5951-5966, 2020. e-Pub 2020. PMID: 33016929.
- Liang J, Wang L, Wang C, Shen J, Su B, Marisetty AL, Fang D, Kassab C, Jeong KJ, Zhao W, Lu Y, Jain AK, Zhou Z, Liang H, Sun SC, Lu C, Xu ZX, Yu Q, Shao S, Chen X, Gao M, Claret FX, Ding Z, Chen J, Chen P, Barton MC, Peng G, Mills GB, Heimberger AB. Verteporfin inhibits PD-L1 through autophagy and the STAT1-IRF1-TRIM28 signaling axis, exerting antitumor efficacy. Cancer Immunol Res 8(7):952-965, 2020. e-Pub 2020. PMID: 32265228.
- McGrail DJ, Garnett J, Yin J, Dai H, Shih DJH, Lam TNA, Li Y, Sun C, Li Y, Schmandt R, Wu JY, Hu L, Liang Y, Peng G, Jonasch E, Menter D, Yates MS, Kopetz S, Lu KH, Broaddus R, Mills GB, Sahni N, Lin SY. Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. Cancer Cell 37(3):371-386.e12, 2020. e-Pub 2020. PMID: 32109374.
- Wang B, Thapa S, Zhou T, Liu H, Li L, Peng G, Yu S. Cancer-related fatigue and biochemical parameters among cancer patients with different stages of sarcopenia. Support Care Cancer 28(2):581-588, 2020. e-Pub 2019. PMID: 31102055.
- Wang R, Song S, Harada K, Ghazanfari Amlashi F, Badgwell B, Pizzi MP, Xu Y, Zhao W, Dong X, Jin J, Wang Y, Scott A, Ma L, Huo L, Vicente D, Blum Murphy M, Shanbhag N, Tatlonghari G, Thomas I, Rogers J, Kobayashi M, Vykoukal J, Estrella JS, Roy-Chowdhuri S, Han G, Zhang S, Mao X, Song X, Zhang J, Gu J, Johnson RL, Calin GA, Peng G, Lee JS, Hanash SM, Futreal A, Wang Z, Wang L, Ajani JA. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut 69(1):18-31, 2020. e-Pub 2019. PMID: 31171626.
- Hu G, Tu W, Yang L, Peng G, Yang L. ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application. Cancer Lett 473:148-155. e-Pub 2020. PMID: 31911080.
- Zou J, Qin W, Yang L, Wang L, Wang Y, Shen J, Xiong W, Yu S, Song S, Ajani JA, Lin SY, Mills GB, Yuan X, Chen J, Peng G. Genetic alterations and expression characteristics of ARID1A impact tumor immune contexture and survival in early-onset gastric cancer. Am J Cancer Res 10(11):3947-3972, 2020. e-Pub 2020. PMID: 33294279.
- Yin Y, Liu W, Shen Q, Zhang P, Wang L, Tao R, Li H, Ma X, Zeng X, Cheong JH, Song S, Ajani JA, Mills GB, Tao K, Peng G. The DNA endonuclease Mus81 regulates ZEB1 expression and serves as a target of BET4 inhibitors in gastric cancer. Mol Cancer Ther 18(8):1439-1450, 2019. e-Pub 2019. PMID: 31142662.
- Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Kim SB, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis 40(7):936, 2019. e-Pub 2019. PMID: 31063534.
- Cao WM, Zheng YB, Gao Y, Ding XW, Sun Y, Huang Y, Lou CJ, Pan ZW, Peng G, Wang XJ. Comprehensive mutation detection of BRCA1/2 genes reveals large genomic rearrangements contribute to hereditary breast and ovarian cancer in Chinese women. BMC Cancer 19(1):551, 2019. e-Pub 2019. PMID: 31174498.
- Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, Ju Z, Vellano CP, Lu Y, Li Y, Jeong KJ, Ding Z, Liang J, Wang SW, Dai H, Lee S, Sahni N, Mercado-Uribe I, Kim TB, Chen K, Lin SY, Peng G, Westin SN, Liu J, O'Connor MJ, Yap TA, Mills GB. Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. Cancer Cell 35(6):851-867.e7, 2019. PMID: 31185210.
- Lin T, Lin TC, McGrail DJ, Bhupal PK, Ku YH, Zhang W, Meng L, Lin SY, Peng G, Tsai RYL. Nucleostemin reveals a dichotomous nature of genome maintenance in mammary tumor progression. Oncogene 38(20):3919-3931, 2019. e-Pub 2019. PMID: 30692636.
- Chang L, Shen L, Zhou H, Gao J, Pan H, Zheng L, Armstrong B, Peng Y, Peng G, Zhou BP, Rosen ST, Shen B. ITCH nuclear translocation and H1.2 polyubiquitination negatively regulate the DNA damage response. Nucleic Acids Res 47(2):824-842, 2019. e-Pub 2018. PMID: 30517763.
- Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, Yap TA, Mills GB, Peng G. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res 79(2):311-319, 2019. e-Pub 2018. PMID: 30482774.
- Yu Y, Pham N, Xia B, Papusha A, Wang G, Yan Z, Peng G, Chen K, Ira G. Dna2 nuclease deficiency results in large and complex DNA insertions at chromosomal breaks. Nature 564(7735):287-290, 2018. e-Pub 2018. PMID: 30518856.
- Jiang Y, Qian X, Shen J, Wang Y, Li X, Liu R, Xia Y, Chen Q, Peng G, Lin SY, Lu Z. Author Correction: Local generation of fumarate promotes DNA repair through inhibition of histone H3 demethylation. Nat Cell Biol 20(10):1226, 2018. e-Pub 2018. PMID: 29632342.
- Hsieh HJ, Zhang W, Lin SH, Yang WH, Wang JZ, Shen J, Zhang Y, Lu Y, Wang H, Yu J, Mills GB, Peng G . Systems biology approach reveals a link between mTORC1 and G2/M DNA damage checkpoint recovery. Nat Commun 9(1):3982, 2018. e-Pub 2018. PMID: 30266942.
- Shen J, Ju Z, Zhao W, Wang L, Peng Y, Ge Z, Nagel ZD, Zou J, Wang C, Kapoor P, Ma X, Ma D, Liang J, Song S, Liu J, Samson LD, Ajani JA, Li GM, Liang H, Shen X, Mills GB, Peng G . ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nature Medicine 24(5):556-562, 2018. e-Pub 2018. PMID: 29736026.
- Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, Vellano CP, Ju Z, Zhao W, Zhang D, Lu Y, Meric-Bernstam F, Yap TA, Hattersley M, O'Connor MJ, Chen H, Fawell S, Lin SY, Peng G, Mills GB. BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell 33(3):401-416.e8, 2018. PMID: 29533782.
- Peng G, Mills GB. Surviving ovarian cancer: an affair between defective DNA repair and RB1. Clin Cancer Res 24(3):508-510, 2018. e-Pub 2017. PMID: 29191971.
- Zhang L, Peng Y, Peng G. Mismatch repair-based stratification for immune checkpoint blockade therapy. Am J Cancer Res 8(10):1977-1988, 2018. e-Pub 2018. PMID: 30416850.
- Wang C, Zou J, Ma X, Wang E, Peng G. Mechanisms and implications of ADAR-mediated RNA editing in cancer. Cancer Lett 411:27-34, 2017. e-Pub 2017. PMID: 28974449.
- Zhang L, Peng Y, Uray IP, Shen J, Wang L, Peng X, Brown PH, Tu W, Peng G. Natural product β-thujaplicin inhibits homologous recombination repair and sensitizes cancer cells to radiation therapy. DNA Repair (Amst) 60:89-101, 2017. e-Pub 2017. PMID: 29112893.
- Luo CW, Wang JY, Hung WC, Peng G, Tsai YL, Chang TM, Chai CY, Lin CH, Pan MR. G9a governs colon cancer stem cell phenotype and chemoradioresistance through PP2A-RPA axis-mediated DNA damage response. Radiother Oncol 124(3):395-402, 2017. e-Pub 2017. PMID: 28351524.
- Zhang L, Shen J, Yin Y, Peng Y, Wang L, Hsieh HJ, Shen Q, Brown PH, Tao K, Uray IP, Peng G. Identifying Cell Cycle Modulators That Selectively Target ARID1A Deficiency Using High-Throughput Image-Based Screening. SLAS Discov 22(7):813-826, 2017. e-Pub 2017. PMID: 28297605.
- Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, Chen X, Vellano CP, Jeong KJ, Ng PK, Eterovic AKB, Bhola NH, Lu Y, Westin SN, Grandis JR, Lin SY, Scott KL, Peng G, Brugge J, Mills GB. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med 9(392), 2017. PMID: 28566428.
- Kumar S, Peng X, Daley J, Yang L, Shen J, Nguyen N, Bae G, Niu H, Peng Y, Hsieh HJ, Wang L, Rao C, Stephan CC, Sung P, Ira G, Peng G. Inhibition of DNA2 nuclease as a therapeutic strategy targeting replication stress in cancer cells. Oncogenesis 6(4):e319, 2017. e-Pub 2017. PMID: 28414320.
- Hsieh HJ, Peng G. Cellular responses to replication stress: implications in cancer biology and therapy. DNA Repair (Amst) 49:9-20, 2017. e-Pub 2016. PMID: 27908669.
- Peng Y, Scott P, Tao R, Wang H, Wu Y, Peng G. Dissect the Dynamic Molecular Circuits of Cell Cycle Control through Network Evolution Model. Biomed Res Int 2017:2954351, 2017. e-Pub 2017. PMID: 28466007.
- Yin Y, Shen Q, Zhang P, Tao R, Chang W, Li R, Xie G, Liu W, Zhang L, Kapoor P, Song S, Ajani J, Mills GB, Chen J, Tao K, Peng G. Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. Am J Cancer Res 7(3):473-483, 2017. e-Pub 2017. PMID: 28401005.
- Zou J, Wang C, Ma X, Wang E, Peng G. APOBEC3B, a molecular driver of mutagenesis in human cancers. Cell Biosci 7:29, 2017. e-Pub 2017. PMID: 28572915.
- Mo W, Liu Q, Lin CC, Dai H, Peng Y, Liang Y, Peng G, Meric-Bernstam F, Mills GB, Li K, Lin SY. mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer. Clin Cancer Res 22(7):1699-712, 2016. e-Pub 2015. PMID: 26546619.
- Huang SJ, Tu, W, Ju ZL, Poage GM, Cai CR, Brewster A, Lin SY, Mills GB, Wang H, Peng G. A five-gene signature inferred from transcriptome profiling of homologous recombinant-mediated DNA repair predicts clinical outcome of patients with cancer. Jacobs Journal of Biomarkers 2(1):014, 2016.
- Jiang Y, Qian X, Shen J, Wang Y, Li X, Liu R, Xia Y, Chen Q, Peng G, Lin SY, Lu Z. Local generation of fumarate promotes DNA repair through inhibition of histone H3 demethylation. Nat Cell Biol 17(9):1158-68, 2015. e-Pub 2015. PMID: 26237645.
- Shen J, Peng Y, Wei L, Zhang W, Yang L, Lan L, Kapoor P, Ju Z, Mo Q, Shih IeM, Uray IP, Wu X, Brown PH, Shen X, Mills GB, Peng G. ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. Cancer Discov 5(7):752-67, 2015. e-Pub 2015. PMID: 26069190.
- Kapoor P, Bao Y, Xiao J, Espejo A, Yang L, Bedford MT, Peng G, Shen X. Phosphorylation-Dependent Enhancement of Rad53 Kinase Activity through the INO80 Chromatin Remodeling Complex. Mol Cell 58(5):863-9, 2015. e-Pub 2015. PMID: 25959398.
- Garrison JB, Ge C, Che L, Pullum DA, Peng G, Khan S, Ben-Jonathan N, Wang J, Du C. Knockdown of the inhibitor of apoptosis BRUCE sensitizes resistant breast cancer cells to chemotherapeutic agents. J Cancer Sci Ther 7(4):121-126, 2015. PMID: 26191375.
- Kapoor P, Bao Y, Xiao J, Luo J, Shen J, Persinger J, Peng G, Ranish J, Bartholomew B, Shen X. Regulation of Mec1 kinase activity by the SWI/SNF chromatin remodeling complex. Genes Dev 29(6):591-602, 2015. PMID: 25792597.
- Lee HJ, Lan L, Peng G, Chang WC, Hsu MC, Wang YN, Cheng CC, Wei L, Nakajima S, Chang SS, Liao HW, Chen CH, Lavin M, Ang KK, Lin SY, Hung MC. Tyrosine 370 phosphorylation of ATM positively regulates DNA damage response. Cell Res 25(2):225-36, 2015. e-Pub 2015. PMID: 25601159.
- Zhang C, Peng G. Non-coding RNAs: an emerging player in DNA damage response. Mutat Res Rev Mutat Res 763:202-211, 2015. e-Pub 2014. PMID: 25795121.
- Liang J, Xu ZX, Ding Z, Lu Y, Yu Q, Werle KD, Zhou G, Park YY, Peng G, Gambello MJ, Mills GB. Myristoylation confers noncanonical AMPK functions in autophagy selectivity and mitochondrial surveillance. Nat Commun 14(6):7926, 2015. e-Pub 2015. PMID: 26272043.
- Peng Y, Dai H, Wang E, Lin CC, Mo W, Peng G, Lin SY. TUSC4 functions as a tumor suppressor by regulating BRCA1 stability. Cancer Res 75(2):378-86, 2015. e-Pub 2014. PMID: 25480944.
- Zhang B, Wang E, Dai H, Shen J, Hsieh HJ, Lu X, Peng G. Phosphorylation of BRCT-Repeat Inhibitor of hTERT (BRIT1) Coordinates TopBP1 Recruitment and Amplifies ATR Signaling. J Biol Chem 289(49):34284-95, 2014. e-Pub 2014. PMID: 25301947.
- Peng G*, Chun-Jen Lin C, Mo W, Dai H, Park YY, Kim SM, Peng Y, Mo Q, Siwko S, Hu R, Lee JS, Hennessy B, Hanash S, Mills GB, Lin SY. Genome-wide transcriptome profiling of homologous recombination DNA repair. Nat Commun 5:3361, 2014. PMID: 24553445.
- Zhang Y, Wang H, Peng G. Identification of key links in the DNA repair network regulated by tumor suppressors PTEN and BRCA1 through maximum flow analysis. Far East Journal of Mathematical Sciences (FJMS) Special Volume 2013(Part VI):577-586, 2013.
- Zhang B, Wang E, Dai H, Hu R, Liang Y, Li K, Wang G, Peng G*, Lin SY. BRIT1 regulates p53 stability and functions as a tumor suppressor in breast cancer. Carcinogenesis 34(10):2271-80, 2013. e-Pub 2013. PMID: 23729656.
- Meng L, Lin T, Peng G, Hsu JK, Lee S, Lin SY, Tsai RY. Nucleostemin deletion reveals an essential mechanism that maintains the genomic stability of stem and progenitor cells. Proc Natl Acad Sci U S A 110(28):11415-20, 2013. e-Pub 2013. PMID: 23798389.
- Hu R, Wang E, Peng G, Dai H, Lin SY. Zinc Finger Protein 668 interacts with Tip60 to promote H2AX acetylation after DNA damage. Cell Cycle 12(13):2033-41, 2013. e-Pub 2013. PMID: 23777805.
- Wan G, Zhang X, Langley RR, Liu Y, Hu X, Han C, Peng G, Ellis LM, Jones SN, Lu X. DNA damage-induced nuclear export of precursor microRNAs is regulated by the ATM-AKT pathway. Cell Rep 3(6):2100-12, 2013. e-Pub 2013. PMID: 23791529.
- Wan G, Mathur R, Hu X, Liu Y, Zhang X, Peng G, Lu X. Long non-coding RNA ANRIL (CDKN2B-AS) is induced by the ATM-E2F1 signaling pathway. Cell Signal 25(5):1086-95, 2013. e-Pub 2013. PMID: 23416462.
- Wang H, Peng G. Mathematical Model of Dynamic Protein Interactions Regulating p53 Protein Stability for Tumor Suppression. Comput Math Methods Med 2013:358980, 2013. e-Pub 2013. PMID: 24454532.
- Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Kim SB, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis 33(10):1843-53, 2012. e-Pub 2012. PMID: 22581827.
- Peng G*, Dai H, Zhang W, Hsieh HJ, Pan MR, Park YY, Tsai RY, Bedrosian I, Lee JS, Ira G, Lin SY. Human nuclease/helicase DNA2 alleviates replication stress by promoting DNA end resection. Cancer Res 72(11):2802-13, 2012. e-Pub 2012. PMID: 22491672.
- Pan MR, Hsieh HJ, Dai H, Hung WC, Li K, Peng G*, Lin SY. Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair and its deficiency sensitizes cells to poly (ADP-ribose) polymerase (PARP) inhibitor treatment. J Biol Chem 287(9):6764-72, 2012. e-Pub 2012. PMID: 22219182.
- Hu R, Peng G, Dai H, Breuer EK, Stemke-Hale K, Li K, Gonzalez-Angulo AM, Mills GB, Lin SY. ZNF668 functions as a tumor suppressor by regulating p53 stability and function in breast cancer. Cancer Res 71(20):6524-6534, 2011. e-Pub 2011. PMID: 21852383.
- Zhang W, Peng G, Lin SY, Zhang P. DNA damage response is suppressed by high CDK1 activity in mitotic mammalian cells. J Biol Chem 286(41):35899-905, 2011. e-Pub 2011. PMID: 21878640.
- Pan MR, Peng G*, Hung WC, Lin SY. Monoubiquitination of H2AX Protein Regulates DNA Damage Response Signaling. J Biol Chem 286(32):28599-607, 2011. e-Pub 2011. PMID: 21676867.
- Tian L, Peng G, Parant JM, Leventaki V, Drakos E, Zhang Q, Parker-Thornburg J, Shackleford TJ, Dai H, Lin SY, Lozano G, Rassidakis GZ, Claret FX. Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair. Oncogene 29(46):6125-37, 2010. e-Pub 2010. PMID: 20802511.
- Bellodi C, Krasnykh O, Haynes N, Theodoropoulou M, Peng G, Montanaro L, Ruggero D. Loss of function of the tumor suppressor DKC1 perturbs p27 translation control and contributes to pituitary tumorigenesis. Cancer Res 70(14):6026-35, 2010. e-Pub 2010. PMID: 20587522.
- Liang Y, Gao H, Lin SY, Peng G, Huang X, Zhang P, Goss JA, Brunicardi FC, Multani AS, Chang S, Li K. BRIT1/MCPH1 is essential for mitotic and meiotic recombination DNA repair and maintaining genomic stability in mice. PLoS Genet 6(1):e1000826, 2010. e-Pub 2010. PMID: 20107607.
- Peng G, Yim EK, Dai H, Jackson AP, Burgt Iv, Pan MR, Hu R, Li K, Lin SY. BRIT1/MCPH1 links chromatin remodeling to DNA damage response. Nat Cell Biol 11(7):865-72, 2009. e-Pub 2009. PMID: 19525936.
- Yim EK, Peng G, Dai H, Hu R, Li K, Lu Y, Mills GB, Meric-Bernstam F, Hennessy BT, Craven RJ, Lin SY. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 15(4):304-14, 2009. PMID: 19345329.
- Peng G, Wargovich MJ, Dixon DA. Anti-proliferative effects of green tea polyphenol EGCG on Ha-Ras-induced transformation of intestinal epithelial cells. Cancer Lett 238(2):260-70, 2006. e-Pub 2005. PMID: 16157446.
- Peng G, Dixon DA, Muga SJ, Smith TJ, Wargovich MJ. Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis. Mol Carcinog 45(5):309-19, 2006. PMID: 16508969.
- Yoon A, Peng G*, Brandenburger Y, Brandenburg Y, Zollo O, Xu W, Rego E, Ruggero D. Impairments in IRES-mediated translational control underlie X-linked dyskeratosis congenita. Science 312(5775):902-906, 2006. PMID: 16690864.
Editorials
- Peng G, Woodman SE, Mills GB. RADical response puts an exceptional responder in CHKmate: a synthetic lethal curative response to DNA-damaging chemotherapy?. Cancer Discov 4(9):988-90, 2014. PMID: 25185187.
Grant & Contract Support
| Title: | Mechanisms of radioresistance and strategies for radiosensitization in OCCC |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
Patient Reviews
CV information above last modified July 15, 2024